Positron emission tomography in breast cancer: 18F- FDG and other radiopharmaceuticals

被引：5
作者：
Iakovou I. [1 ]
Giannoula E. [1 ,2 ]
Gkantaifi A. [3 ]
Levva S. [4 ]
Frangos S. [5 ]
机构：
[1] Third Department of Nuclear Medicine, Medical School, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki
[2] Nuclear Medicine Department, “Theagenion” Cancer Hospital, Thessaloniki
[3] Radiotherapy Department, Interbalkan Medical Center, 10 Asclepiou Str., Pylaia, Zip Code 57001, Thessaloniki
[4] Department of Medical Oncology, Papageorgiou General Hospital, School of Health Science Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki
[5] Department of Nuclear Medicine, Bank of Cyprus Oncology Centre, 32 Acropoleos Avenue, Strovolos, 2006, Nicosia
来源：
European Journal of Hybrid Imaging | / 2卷 / 1期
关键词：
Breast cancer; Diagnosis; Immunohistochemistry; Molecular imaging; Nuclear medicine; Positron emission tomography (PET); Radiopharmaceuticals; Staging; Treatment;
D O I：
10.1186/s41824-018-0039-x
中图分类号：
学科分类号：
摘要：
Background: Breast cancer heterogeneity reflects the complex biology of this disease. Breast cancer subtypes, as identified either by immunohistochemistry (IHC) or by gene expression analysis, present different molecular characteristics and prognosis. In this context, molecular imaging techniques providing functional information, contribute in evaluating response to treatment and long-term prognosis among different subtypes. Nuclear imaging diagnosis modalities play an important role for conducting research on cancer biology and developing new treatment approaches. Positron Emission Tomography (PET) is a radionuclide based imaging method that has the potential to locate the tumor, define its staging, and monitor its response to treatment. Results: In the current study, we will review the utility of the most widely used molecular imaging technique, 18F-fluorodeoxyglucose (18F-FDG) PET, in order to determine the relationship between standardized uptake values (SUVs) and immunohistopathological factors, as well as to clarify whether PET is able to predict breast cancer phenotypes. Moreover, we will discuss the rising development of new radiopharmaceuticals in PET imaging, such as 18F-fluoro-17-estradiol (FES), 18F-fluoro-l-thymidine (FLT), 18F-fluoromisonidazole (FISO), and 89Zr-immuno-PET, which give more information about tumor characteristics. Conclusions: In order to improve clinical decision making, enabling hereafter more successful individualized therapies, it is imperative to combine PET radiopharmaceuticals and imaging techniques of critical biologic and pathologic phenomena, including ER, PR and HER2 expression, angiogenesis, hypoxia, apoptosis and metabolic changes in the microenviroment of breast tumors. © 2018, The Author(s).
引用
收藏
相关论文
共 107 条
[1]  
Adejolu M., Huo L., Rohren E., Et al., False-positive lesions mimicking breast cancer on FDG PET and PET/CT, AJR Am J Roentgenol, 198, 3, pp. W304-W314, (2012)
[2]  
Aide N., Lasnon C., Veit-Haibach P., Et al., EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies, Eur J Nucl Med Mol Imaging, 44, pp. 17-31, (2017)
[3]  
Cancer Facts and Figures 2017, (2017)
[4]  
Arpino G., Clark G.M., Mohsin S., Et al., Adenoid cystic carcinoma of the breasr, Cancer, 94, pp. 2119-2127, (2002)
[5]  
Avril N., Rosi C.A., Schelling M., Et al., Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations, J Clin Oncol, 18, pp. 3495-3502, (2000)
[6]  
Barthel H., Wilson H., Collingridge D.R., Et al., In vivo evaluation of [18F] fluoroetanidazole as a new marker for imaging tumor hypoxia with positron emission tomography, Br J Cancer, 90, 11, pp. 2232-2242, (2004)
[7]  
Basu S., Chen W., Tchou J., Et al., Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization, Cancer, 112, 5, pp. 995-1000, (2008)
[8]  
Baum R.P., Prasad V., Muller D., Et al., Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules, J Nucl Med, 51, 6, pp. 892-897, (2010)
[9]  
Bauwens M., De Saint-Hubert M., Devos E., Et al., Site-specific 68Ga-labeled Annexin A5 as a PET imaging agent for apoptosis, Nucl Med Biol, 38, 3, pp. 381-392, (2011)
[10]  
Beer A.J., Niemeyer M., Carlsen J., Et al., Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET, J Nucl Med, 49, 2, pp. 255-259, (2008)
12345678910